Results 11 to 20 of about 494,114 (145)
Bispecific antibodies for viral immunotherapy [PDF]
Human Vaccines & Immunotherapeutics, 2017 Bispecific antibody engineering, in which binding specificities toward 2 distinct epitopes are combined into a single molecule, can greatly enhance immunotherapeutic properties of monoclonal antibodies.
Elisabeth K. Nyakatura +2 more
doaj +4 more sources
Viral antibodies in multiple sclerosis [PDF]
The Italian Journal of Neurological Sciences, 1982 The sera of 176 MS patients and of 150 healthy adult controls were assayed for antibodies against mumps, rubella, Sendai and herpes simplex viruses, a higher prevalence of measles c.f.a. having already been demonstrated in the MS patients. The CSF of 48 of the MS patients were subjected to the same tests.
S. Barbesti +3 more
openaire +3 more sources
Platelet antibodies in viral hepatitis
The Turkish Journal of Pediatrics, 1987 O Hasdal, S Ozsoylu, N Koçak
doaj +2 more sources
Viral Antibodies in Diabetes Mellitus [PDF]
BMJ, 1969 Sera from 123 patients with diabetes mellitus of recent onset, 155 patients with diabetes of more than two years' duration, and 250 normal persons were collected over a period of two and a half years. All sera were tested for neutralizing antibody to Coxsackie virus types B1-6, and a sample was tested for complement-fixing antibody to a number of viral,
M. L. Kinsley +4 more
openaire +2 more sources
Viral antibodies in infectious mononucleosis [PDF]
FEMS Immunology & Medical Microbiology, 1994 Patients with Epstein-Barr virus (EBV) infectious mononucleosis (IM) usually develop heterophilic antibodies and some autoantibodies. Antibodies to rubella, measles, adeno-, entero-, herpes simplex, cytomegalo- and varicella-zoster viruses were titrated in sera from IM patients and matched healthy controls using the complement fixation test (CFT) and ...
May Britt Kalvenes +5 more
openaire +3 more sources
Engineered antibodies to combat viral threats [PDF]
Nature, 2020 As the COVID-19 pandemic rages globally, interest in antiviral treatments has never been higher. Antibodies are key defence components, and engineering them to better exploit their natural functions might boost therapeutic options. Modification of the antibody Fc domain boosts defence responses.
Cragg, Mark, Yu, Xiaojie
openaire +4 more sources
Viral Antibodies in Chronic Fatigue Syndrome [PDF]
Clinical Infectious Diseases, 1995 Item does not contain ...
Swanink, C.M.A. +6 more
openaire +6 more sources
Viral interference with antibody and complement
Seminars in Cell & Developmental Biology, 1998 Viruses have evolved strategies to evade immunity mediated by antibody and complement. Herpesviruses and coronaviruses encode IgG Fc binding proteins that inhibit IgG activity, enabling the virus or infected cell to escape antibody attack. Herpesviruses, vaccinia virus and HIV-1 have the capacity to interfere with complement, either by incorporation of
Harvey M. Friedman +2 more
openaire +2 more sources
Antibody barriers to going viral [PDF]
Journal of Experimental Medicine, 2019 Antibody neutralization of a virus in vitro is often associated with protection against viral exposure in vivo, but the mechanisms operational in vivo are often unclear. By investigating a large number of antibodies, Earnest et al. (https://doi.org/10.1084/jem.20190736) show the importance of antibody effector function in neutralizing antibody ...
openaire +2 more sources
Bio-Protocol, 2021 The recombinant receptor-binding domain (RBD) of the viral spike protein from SARS-CoV-1 and 2 are reliable antigens for detecting viral-specific antibodies in humans.
Bruno Segovia-Chumbez +4 more
doaj +1 more source